Search - tctmd.com

Displaying 21 - 31 of 31

Sort: Relevancy | Date

Presentation TCT 2019

TWILIGHT Thrombogenicity Substudy: Impact of Ticagrelor Alone vs. Ticagrelor Plus Aspirin on Ex-Vivo Blood Thrombogenicity in High-Risk Patients Undergoing PCI

Presenter: Usman Baber

September 26, 2019

https://www.tctmd.com/news/ideal-lm-probes-short-dapt-and-bioabsorbable-polymer-stent-left-main-disease

News Conference News TCT 2019

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

Michael O'Riordan

September 26, 2019

Presentation TCT 2019

TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor-Plus-Aspirin Beginning at 3 Months in High-Risk Patients Undergoing PCI

Presenter: Roxana Mehran

September 26, 2019

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

Presentation TCT 2019

Insights From TWILIGHT

Presenter: Usman Baber

September 26, 2019

News Conference News TCT 2019

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

Shelley Wood

September 19, 2019

Presentation TCT 2017

Predicting the Future: Will the Ongoing TWILIGHT and GLOBAL LEADERS Trials Change The Current Recommended Approach to Chronic Antiplatelet Therapy?

Presenter: C. Michael Gibson, Stephan Windecker, Eric R. Bates

October 30, 2017

Presentation TCT 2016

Rationale for and Design of TWILIGHT and GLOBAL LEADERS: What I Expect the Findings to Be But What Wont Surprise Me!

Presenter: Jorge Gaspar, C. Michael Gibson

October 30, 2016

Presentation TCT 2015

From WOEST, DAPT, and PEGASUS to GLOBAL LEADERS and TWILIGHT: What Answers Can We Expect (and Not Expect) From GLOBAL LEADERS and TWILIGHT?

Presenter: Ori Ben-Yehuda, Ajay J. Kirtane, Roxana Mehran

October 11, 2015

Video

» Interview

Dr. C. Michael Gibson Talks With Dr. Usman Baber About the TWILIGHT Thrombogenicity Substudy: Impact of Ticagrelor Alone vs. Ticagrelor Plus Aspirin on Ex-Vivo Blood Thrombogenicity in High-Risk Patients Undergoing PCI

September 28, 2019

Video

» Interview

Dr. C. Michael Gibson Talks With Dr. Roxana Mehran About TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor Plus Aspirin Beginning at 3 Months in High-Risk Patients Undergoing PCI

September 27, 2019

Advertisement

TWILIGHT Thrombogenicity Substudy: Impact of Ticagrelor Alone vs. Ticagrelor Plus Aspirin on Ex-Vivo Blood Thrombogenicity in High-Risk Patients Undergoing PCI

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor-Plus-Aspirin Beginning at 3 Months in High-Risk Patients Undergoing PCI

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Insights From TWILIGHT

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

Predicting the Future: Will the Ongoing TWILIGHT and GLOBAL LEADERS Trials Change The Current Recommended Approach to Chronic Antiplatelet Therapy?

Rationale for and Design of TWILIGHT and GLOBAL LEADERS: What I Expect the Findings to Be But What Wont Surprise Me!

From WOEST, DAPT, and PEGASUS to GLOBAL LEADERS and TWILIGHT: What Answers Can We Expect (and Not Expect) From GLOBAL LEADERS and TWILIGHT?

Dr. C. Michael Gibson Talks With Dr. Usman Baber About the TWILIGHT Thrombogenicity Substudy: Impact of Ticagrelor Alone vs. Ticagrelor Plus Aspirin on Ex-Vivo Blood Thrombogenicity in High-Risk Patients Undergoing PCI

Dr. C. Michael Gibson Talks With Dr. Roxana Mehran About TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor Plus Aspirin Beginning at 3 Months in High-Risk Patients Undergoing PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content